<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00001502</url>
  </required_header>
  <id_info>
    <org_study_id>960068</org_study_id>
    <secondary_id>96-C-0068</secondary_id>
    <nct_id>NCT00001502</nct_id>
  </id_info>
  <brief_title>A Pediatric Phase I Trial of RMP-7 and Carboplatin in Brain Tumors</brief_title>
  <official_title>Pediatric Phase I Trial of RMP-7 and Carboplatin in Brain Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      The presence of a highly selective blood-brain barrier (BBB) at the level of the brain&#xD;
      capillary endothelium prevents chemotherapeutic agents from attaining therapeutic&#xD;
      concentrations at the target site. RMP-7 is a synthetic bradykinin analog which specifically&#xD;
      binds to B2 receptors expressed on the brain capillary endothelial cells and preferentially&#xD;
      increases capillary permeability within CNS tumors. Carboplatin is an anticancer agent with&#xD;
      preclinical and clinical antitumor activity against a variety of brain tumors. A pediatric&#xD;
      phase I trial of the combination of RMP-7 and carboplatin will be conducted to determine the&#xD;
      maximum tolerated dose of RMP-7 in children with refractory brain tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The presence of a highly selective blood-brain barrier (BBB) at the level of the brain&#xD;
      capillary endothelium prevents chemotherapeutic agents from attaining therapeutic&#xD;
      concentrations at the target site. RMP-7 is a synthetic bradykinin analog which specifically&#xD;
      binds to B2 receptors expressed on the brain capillary endothelial cells and preferentially&#xD;
      increases capillary permeability within CNS tumors. Carboplatin is an anticancer agent with&#xD;
      preclinical and clinical antitumor activity against a variety of brain tumors. A pediatric&#xD;
      phase I trial of the combination of RMP-7 and carboplatin will be conducted to determine the&#xD;
      maximum tolerated dose of RMP-7 in children with refractory brain tumors.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 1996</start_date>
  <completion_date>March 2000</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>30</enrollment>
  <condition>Brain Neoplasms</condition>
  <condition>Glioma</condition>
  <condition>Medulloblastoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RMP-7 and carboplatin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
        Histologically confirmed brain tumor including but not limited to the following: Anaplastic&#xD;
        astrocytoma, Glioblastoma multiforme, Low-grade glioma, Ependymoma, Medulloblastoma, Pineal&#xD;
        tumors, Chiasmal glioma, Craniopharyngioma, Brain stem glioma (requirement for histologic&#xD;
        diagnosis may be waived).&#xD;
&#xD;
        Disease refractory to standard therapy or no standard chemotherapy exists and ineligible&#xD;
        for potential curative surgery or radiotherapy.&#xD;
&#xD;
        Measurable or evaluable disease on radiographic studies with evidence of progression on&#xD;
        prior chemotherapy or radiotherapy or persistent disease after surgery.&#xD;
&#xD;
        PRIOR/CURRENT THERAPY:&#xD;
&#xD;
        See Disease Characteristics&#xD;
&#xD;
        At least 6 months since carboplatin.&#xD;
&#xD;
        At least 3 weeks since myelosuppressive therapy.&#xD;
&#xD;
        Patients who received stem cell or bone marrow rescue after nitrosourea therapy are&#xD;
        eligible after 3 weeks if they have recovered from hematologic toxicities of their prior&#xD;
        therapy.&#xD;
&#xD;
        Concurrent steroids allowed if dose stable for at least 2 weeks prior to entry.&#xD;
&#xD;
        Recovered from toxic effects of any prior therapy.&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age: 21 and under.&#xD;
&#xD;
        Performance status: ECOG 0-2.&#xD;
&#xD;
        Life expectancy: At least 8 weeks.&#xD;
&#xD;
        HEMATOLOGIC:&#xD;
&#xD;
        Absolute granulocyte count greater than 1,500/mm(3).&#xD;
&#xD;
        Platelet count greater than 100,000/mm(3) (at least 75,000/mm(3) in patients with prior&#xD;
        bone marrow transplantation or craniospinal irradiation).&#xD;
&#xD;
        Hemoglobin greater than 8.0 g/dL.&#xD;
&#xD;
        HEPATIC:&#xD;
&#xD;
        Bilirubin no greater than 2 times normal.&#xD;
&#xD;
        ALT no greater than 2 times normal.&#xD;
&#xD;
        RENAL:&#xD;
&#xD;
        Creatinine within normal limits for age as follows:&#xD;
&#xD;
        Age (in years) -- Creatinine (in mg/dL):&#xD;
&#xD;
        Younger than 5 -- no greater than 1.2;&#xD;
&#xD;
        5-10 -- no greater than 1.5;&#xD;
&#xD;
        10-15 -- no greater than 1.8;&#xD;
&#xD;
        Older than 15 -- no greater than 2.4.&#xD;
&#xD;
        OTHER:&#xD;
&#xD;
        No significant systemic illness.&#xD;
&#xD;
        No pregnant or nursing women.&#xD;
&#xD;
        Negative pregnancy test required of fertile women.&#xD;
&#xD;
        Effective contraception required of fertile patients.&#xD;
&#xD;
        Durable power of attorney required of all patients 18-21 years of age.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Cancer Institute (NCI)</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Clements JA. The human kallikrein gene family: a diversity of expression and function. Mol Cell Endocrinol. 1994 Feb;99(1):C1-6. doi: 10.1016/0303-7207(94)90138-4. No abstract available.</citation>
    <PMID>8187947</PMID>
  </reference>
  <reference>
    <citation>Straub JA, Akiyama A, Parmar P. In vitro plasma metabolism of RMP-7. Pharm Res. 1994 Nov;11(11):1673-6. doi: 10.1023/a:1018986510570. No abstract available.</citation>
    <PMID>7870689</PMID>
  </reference>
  <reference>
    <citation>Inamura T, Nomura T, Bartus RT, Black KL. Intracarotid infusion of RMP-7, a bradykinin analog: a method for selective drug delivery to brain tumors. J Neurosurg. 1994 Nov;81(5):752-8. doi: 10.3171/jns.1994.81.5.0752.</citation>
    <PMID>7931623</PMID>
  </reference>
  <verification_date>February 2000</verification_date>
  <study_first_submitted>November 3, 1999</study_first_submitted>
  <study_first_submitted_qc>December 9, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2002</study_first_posted>
  <last_update_submitted>March 3, 2008</last_update_submitted>
  <last_update_submitted_qc>March 3, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2008</last_update_posted>
  <keyword>Blood-Brain Barrier</keyword>
  <keyword>Bradykinin</keyword>
  <keyword>Children</keyword>
  <keyword>Glioma</keyword>
  <keyword>Medulloblastoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Medulloblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

